Patents by Inventor Jack Lile
Jack Lile has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10947521Abstract: A process for producing recombinant trypsin from prokaryote host cells in high yield and high specific activity is described. In particular, a process for producing recombinant trypsin from E. coli is described.Type: GrantFiled: November 13, 2015Date of Patent: March 16, 2021Assignee: MERCK SHARP & DOHME CORP.Inventors: Mark C. Sleevi, Jack Lile
-
Patent number: 10301611Abstract: A process for refolding recombinant chymotrypsin produced from prokaryote host cells is described. In particular, the present invention provides a process for refolding recombinant chymotrypsin produced from E. coli is described.Type: GrantFiled: November 13, 2015Date of Patent: May 28, 2019Assignee: MERCK SHARP & DOHME CORP.Inventors: Mark C. Sleevi, Jack Lile, Bryn Grimison
-
Publication number: 20170342397Abstract: A process for refolding recombinant chymotrypsin produced from prokaryote host cells is described. In particular, the present invention provides a process for refolding recombinant chymotrypsin produced from E. coli is described.Type: ApplicationFiled: November 13, 2015Publication date: November 30, 2017Applicant: Merck Sharp & Dohme Corp.Inventors: Mark C. Sleevi, Jack Lile, Bryn Grimison
-
Publication number: 20170335308Abstract: A process for producing recombinant trypsin from prokaryote host cells in high yield and high specific activity is described. In particular, a process for producing recombinant trypsin from E. coli is described.Type: ApplicationFiled: November 13, 2015Publication date: November 23, 2017Applicant: Merck Sharp & Dohme Corp.Inventors: Mark C. Sleevi, Jack Lile
-
Patent number: 7226758Abstract: A novel neurotrophic factor referred to as glial cell line-derived neurotrophic factor (GDNF) has been identified and isolated from serum free growth conditioned medium of B49 glioblastoma cells. Rat and human genes encoding GDNF have been cloned and sequenced. A gene encoding GDNF has been subcloned into a vector, and the vector has been used to transform a host cell in order to produce biologically active GDNF in a recombinant DNA process.Type: GrantFiled: September 17, 1992Date of Patent: June 5, 2007Assignee: Amgen Inc.Inventors: Leu-Fen H. Lin, Franklin D. Collins, Daniel H. Doherty, Jack Lile, Susan Bektesh
-
Publication number: 20040175795Abstract: A novel neurotrophic factor referred to as glial derived neurotrophic factor (GDNF) has been identified and isolated from serum free growth conditioned medium of B49 glioblastoma cells. Rat and human genes encoding GDNF have been cloned and sequenced. A gene encoding GDNF has been subcloned into a vector, and the vector has been used to transform a host cell in order to produce biologically active GDNF in a recombinant DNA process.Type: ApplicationFiled: January 14, 2004Publication date: September 9, 2004Applicant: Amgen Inc.Inventors: Leu-Fen H. Lin, Franklin D. Collins, Daniel H. Doherty, Jack Lile, Susan Bektesh
-
Publication number: 20020197675Abstract: A novel neurotrophic factor referred to as glial derived neurotrophic factor (GDNF) has been identified and isolated from serum free growth conditioned medium of B49 glioblastoma cells. Rat and human genes encoding GDNF have been cloned and sequenced. A gene encoding GDNF has been subcloned into a vector, and the vector has been used to transform a host cell in order to produce biologically active GDNF in a recombinant DNA process.Type: ApplicationFiled: November 13, 2001Publication date: December 26, 2002Applicant: Amgen Inc.Inventors: Leu-Fen H. Lin, Franklin D. Collins, Daniel H. Doherty, Jack Lile, Susan Bektesh
-
Patent number: 6362319Abstract: A novel neurotrophic factor referred to as glial derived neurotrophic factor (GDNF) has been identified and isolated from serum free growth conditioned medium of B49 glioblastoma cells. Rat and human genes encoding GDNF have been cloned and sequenced. A gene encoding GDNF has been subcloned into a vector, and the vector has been used to transform a host cell in order to produce biologically active GDNF in a recombinant DNA process.Type: GrantFiled: May 26, 1995Date of Patent: March 26, 2002Assignee: Amgen Inc.Inventors: Leu-Fen H. Lin, Franklin D. Collins, Daniel H. Doherty, Jack Lile, Susan Bektesh
-
Patent number: 6221376Abstract: A novel neurotrophic factor referred to as glial cell line-derived neurotrophic factor (GDNF) has been identified. Genes encoding GDNF have been cloned and sequenced. Methods and devices are disclosed for the delivery of GDNF using either an implantable cell which expresses human GDNF or a biocompatible semipermeable membrane containing genetically engineered cells which express and secrete the neurotrophic factor.Type: GrantFiled: September 22, 1997Date of Patent: April 24, 2001Assignee: Amgen Inc.Inventors: Leu-Fen H. Lin, Franklin D. Collins, Daniel H. Doherty, Jack Lile, Susan Bektesh
-
Patent number: 6093802Abstract: A novel neurotrophic factor referred to as glial cell line-derived neurotrophic factor (GDNF) has been identified and isolated from serum free growth conditioned medium of B49 glioblastoma cells. Rat and human genes encoding GDNF have been cloned and sequenced. A gene encoding GDNF has been subcloned into a vector, and the vector has been used to transform a host cell in order to produce biologically active GDNF in a recombinant DNA process.Type: GrantFiled: May 26, 1995Date of Patent: July 25, 2000Assignee: Amgen Inc.Inventors: Leu-Fen H. Lin, Franklin D. Collins, Daniel H. Doherty, Jack Lile, Susan Bektesh
-
Patent number: 6015572Abstract: A novel neurotrophic factor referred to as glial cell line-derived neurotrophic factor (GDNF) has been identified and isolated from serum free growth medium of B49 glioblastoma cells. Rat and human genes encoding GDNF have been cloned and sequenced. A gene encoding GDNF has been subcloned into a vector, and the vector has been used to transform a host cell in order to produce biologically active GDNF in a recombinant DNA process. An implantable device containing recombinant GDNF secreting cells encapsulated in a semipermeable membrane may be used to treat nerve damage in patients suffering from disorders such as Parkinson's disease.Type: GrantFiled: May 30, 1995Date of Patent: January 18, 2000Assignee: Amgen Inc.Inventors: Leu-Fen H. Lin, Franklin D. Collins, Daniel H. Doherty, Jack Lile, Susan Bektesh
-
Patent number: 5986070Abstract: This invention describes processes for producing mature human members of the NGF/BDNF family of neurotrophic proteins that are fully biologically active. In addition, the gene encoding human BDNF and human BDNF are disclosed. A previously-unreported member of the NGF/BDNF family of neurotrophic proteins, NGF-3, has been identified and a portion of the gene encoding for the NGF-3 has been described.Type: GrantFiled: August 27, 1997Date of Patent: November 16, 1999Assignee: Amgen Inc.Inventors: Frank D. Collins, Jack Lile, Susan Becktesh, Tadahiko Kohno, Drizislav Mismer, deceased
-
Patent number: 5935795Abstract: A novel neurotrophic factor referred to as glial cell line-derived neurotrophic factor (GDNF) has been identified and isolated from serum free growth conditioned medium of B49 glioblastoma cells. Rat and human genes encoding GDNF have been cloned and sequenced. A gene encoding GDNF has been subcloned into a vector and the vector has been used to transform a host cell in order to produce biologically active GDNF in a recombinant DNA process. Antibodies to GDNF are disclosed, as well as methods for identifying members of the GDNF family of neurotrophic factors.Type: GrantFiled: May 26, 1995Date of Patent: August 10, 1999Assignee: Amgen Inc.Inventors: Leu-Fen H. Lin, Franklin D. Collins, Daniel H. Doherty, Jack Lile, Susan Bektesh
-
Patent number: 5606031Abstract: A process for the production of biologically active recombinant neurotrophic factor from the NGF/BDNF family is described. The process is comprised of a) constructing a synthetic neurotrophic factor gene suitable for expression in a bacterial expression system; b) the synthetic neurotrophic factor gene is expressed in a bacterial expression system; c) the neurotrophic factor is solubilized and sulfonylated; d) sulfonylated neurotrophic factor is allowed to refold in the presence of polyethylene glycol and urea; and e) biologically active neurotrophic factor is isolated and purified.Type: GrantFiled: June 27, 1994Date of Patent: February 25, 1997Inventors: Jack Lile, Tadahiko Kohno, Duane Bonam, Mary S. Rosendahl
-
Patent number: 5235043Abstract: This invention describes processes for producing mature human members of the NGF/BDNF family of neurotrophic proteins that are fully biologically active. In addition, the gene encoding human BDNF and processes for obtaining the same are disclosed.A previously-unreported member of the NGF/BDNF family of neurotrophic proteins, NGF-3, has been identified and a portion of the gene encoding for the NGF-3 has been described. Processes for identifying additional previously unreported members of the NGF/BDNF family are also described.Type: GrantFiled: October 9, 1990Date of Patent: August 10, 1993Assignee: Synergen, Inc.Inventors: Frank Collins, Susan Bektesh, Tadahiko Kohno, Jack Lile